Aaron R Folsom1, Jeffrey P Anderson, Julie A Ross. 1. Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, Minnesota55454-1015, USA. folsom@epi.umn.edu
Abstract
BACKGROUND: A recent meta-analysis concluded that there was no overall association between estrogen replacement therapy (ERT) and risk of epithelial ovarian cancer. However, several subsequent studies have suggested that long-term ERT could increase ovarian cancer risk. METHODS: We prospectively examined the association of ERT with epithelial ovarian cancer among 31,381 postmenopausal women in Iowa followed for 15 years. RESULTS: Women who were using ERT at baseline had an elevated multivariate-adjusted relative risk of ovarian cancer (1.7; 95% confidence interval [CI] = 1.1-2.8) compared with never-users. Risk was higher among women who had been using ERT at baseline for more than 5 years (2.5; CI = 1.4-4.5). A time-dependent analysis likewise yielded a relative risk of 1.7 for current ERT use. Former ERT use was not associated with ovarian cancer incidence. CONCLUSIONS: Long duration of ERT use after menopause could increase the risk of epithelial ovarian cancer.
BACKGROUND: A recent meta-analysis concluded that there was no overall association between estrogen replacement therapy (ERT) and risk of epithelial ovarian cancer. However, several subsequent studies have suggested that long-term ERT could increase ovarian cancer risk. METHODS: We prospectively examined the association of ERT with epithelial ovarian cancer among 31,381 postmenopausal women in Iowa followed for 15 years. RESULTS:Women who were using ERT at baseline had an elevated multivariate-adjusted relative risk of ovarian cancer (1.7; 95% confidence interval [CI] = 1.1-2.8) compared with never-users. Risk was higher among women who had been using ERT at baseline for more than 5 years (2.5; CI = 1.4-4.5). A time-dependent analysis likewise yielded a relative risk of 1.7 for current ERT use. Former ERT use was not associated with ovarian cancer incidence. CONCLUSIONS: Long duration of ERT use after menopause could increase the risk of epithelial ovarian cancer.
Authors: Alison J Canchola; Ellen T Chang; Leslie Bernstein; Joan A Largent; Peggy Reynolds; Dennis Deapen; Katherine D Henderson; Giske Ursin; Pamela L Horn-Ross Journal: Cancer Causes Control Date: 2010-10-06 Impact factor: 2.506
Authors: Jonathan Beesley; Susan J Jordan; Amanda B Spurdle; Honglin Song; Susan J Ramus; Suzanne Kruger Kjaer; Estrid Hogdall; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Simon A Gayther; Paul D P Pharoah; Penelope M Webb; Georgia Chenevix-Trench Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-12 Impact factor: 4.254
Authors: Karen J Wernli; Polly A Newcomb; John M Hampton; Amy Trentham-Dietz; Kathleen M Egan Journal: Cancer Causes Control Date: 2008-02-09 Impact factor: 2.506
Authors: Marc T Goodman; Galina Lurie; Pamela J Thompson; Katharine E McDuffie; Michael E Carney Journal: Endocr Relat Cancer Date: 2008-07-30 Impact factor: 5.678
Authors: Marta Szajnik; Miroslaw J Szczepanski; Esther Elishaev; Carmen Visus; Diana Lenzner; Maciej Zabel; Marta Glura; Albert B DeLeo; Theresa L Whiteside Journal: Gynecol Oncol Date: 2012-08-17 Impact factor: 5.482
Authors: Sergio Eduardo Perniconi; Manuel de Jesus Simões; Ricardo Dos Santos Simões; Mauro Abi Haidar; Edmund C Baracat; Jose Maria Soares Journal: Clinics (Sao Paulo) Date: 2008-06 Impact factor: 2.365